Get the Stockscreener App
22.98
2.41%
0.54
After Hours:
23.00
0.02
+0.09%
Pharvaris Nv stock is traded at $22.98, with a volume of 85,993.
It is up +2.41% in the last 24 hours and up +5.27% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$22.44
Open:
$22.52
24h Volume:
85,993
Relative Volume:
0.52
Market Cap:
$1.44B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-8.1385
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-4.49%
1M Performance:
+5.27%
6M Performance:
+94.25%
1Y Performance:
+28.38%
1-Day Range:
$22.52
$23.29
1-Week Range:
$22.07
$24.41
52-Week Range:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
22.98 | 1.44B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
What drives Pharvaris NV stock priceHigh Yield Income Stocks & Fast Profit Trading Ideas - earlytimes.in
Is Pharvaris NV a good long term investmentTrendline Breakouts & Exceptional Return Stocks - earlytimes.in
Analyzing Pharvaris N.V. with multi timeframe chartsEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
How to forecast Pharvaris N.V. trends using time seriesTrade Volume Summary & High Accuracy Trade Signal Alerts - newser.com
Why pension funds invest in Pharvaris N.V. (9EN) stock2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
Combining price and volume data for Pharvaris N.V.July 2025 Breakouts & Weekly Watchlist of Top Performers - newser.com
Pharvaris (NASDAQ:PHVS) Shares Gap DownHere's What Happened - MarketBeat
What analyst consensus says on Pharvaris N.V. stockMarket Growth Report & Fast Momentum Stock Entry Tips - newser.com
Using Bollinger Bands to evaluate Pharvaris N.V.Share Buyback & Growth Focused Stock Reports - newser.com
Can Pharvaris N.V. stock sustain free cash flow growthPortfolio Growth Summary & Consistent Return Investment Signals - newser.com
Heatmap analysis for Pharvaris N.V. and competitors2025 Big Picture & Verified Entry Point Signals - newser.com
Will Pharvaris N.V. (9EN) stock outperform benchmarksQuarterly Performance Summary & Technical Buy Zone Confirmation - newser.com
Is Pharvaris N.V. meeting your algorithmic filter criteria2025 Volatility Report & Risk Managed Investment Signals - newser.com
Is Pharvaris N.V. stock supported by strong cash flowsWeekly Trend Report & Low Risk High Reward Trade Ideas - newser.com
Can Pharvaris N.V. hit a new high this monthInsider Selling & Low Risk High Win Rate Stock Picks - newser.com
Will RAPIDe-3 Data Cement Deucrictibant's Role In HAE Treatment? - RTTNews
Pharvaris (NASDAQ:PHVS) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Pharvaris NV Stock Analysis and ForecastTrading Volume Trends & Low Cost Capital Gains - earlytimes.in
Published on: 2025-09-29 04:55:34 - newser.com
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):